Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
52 hedge funds and large institutions have $396M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 3 closing their positions.
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
44% more funds holding
Funds holding: 36 → 52 (+16)
34% more capital invested
Capital invested by funds: $296M → $396M (+$99.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.82M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.61M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$5.21M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.79M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$12.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.9M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.17M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$226K |
STSA Hedge Fund Activity: Q2 2020 in Review
52 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q2 2020, worth a combined $396M — up 34% from $296M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new STSA positions and 3 closed out — a net gain of 16 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $7.82M. The largest seller was Caxton Corporation, cutting an estimated $12.5M.
- 52 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q2 2020, up from 36 in Q1 2020.
- Funds reported $396M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 34% quarter-over-quarter.
- 19 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of +16 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $7.82M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Caxton Corporation, an estimated $12.5M sold.
Based on aggregated 13F filings for Q2 2020.